TY - JOUR
T1 - Cardiovascular and metabolic monitoring of children and adolescents on antipsychotic treatment: A cross-sectional descriptive study
AU - de la Torre Villalobos, Miquel
AU - Martin-López, Luis Miguel
AU - Fernández Sanmartín, María Isabel
AU - Pujals Altes, Elena
AU - Gasque Llopis, Silvia
AU - Batlle Vila, Santiago
AU - Pérez-Solá, Victor
AU - Novo Navarro, Patricia
AU - Gómez Simón, Isabel
AU - Fresno González, Cristina
AU - Camprodon Rosanas, Ester
AU - Bulbena Vilarrasa, Antonio
PY - 2018/1/1
Y1 - 2018/1/1
N2 - © 2016 SEP y SEPB Background: Cardiovascular and metabolic monitoring of patients on antipsychotic medication is essential. This becomes more important in those of paediatric age, as they are more vulnerable, and also because prescriptions of this kind of drugs are still increasing. Aim: To evaluate the monitoring of cardiovascular and metabolic risk factors in a group of children and young people on antipsychotic medication. Method: A descriptive cross-sectional study was conducted in which a group of 220 patients aged 8-17 years, diagnosed with a mental disorder and on antipsychotic treatment. They were compared to a control group of 199 asthmatic patients not exposed to antipsychotic drugs. Data was extracted from the computerised clinical history ECAP in 2013. Results: The mean age of the children was 12 years (8-17). Risperidone (67%) was the most frequent treatment. The recording of Body Mass Index (BMI) and blood pressure (AP) was 50% in Mental Disorder (MD) patients. A higher number of cardiovascular monitoring physical parameters (weight, height, BMI and BP) were observed in the MD group compared to the control Asthma control group. Altogether, more physical parameters than biochemistry parameters were recorded. Conclusions: This study shows that the recording of cardiovascular parameters and metabolic studies needs to be improved in children and adolescents on treatment with antipsychotics.
AB - © 2016 SEP y SEPB Background: Cardiovascular and metabolic monitoring of patients on antipsychotic medication is essential. This becomes more important in those of paediatric age, as they are more vulnerable, and also because prescriptions of this kind of drugs are still increasing. Aim: To evaluate the monitoring of cardiovascular and metabolic risk factors in a group of children and young people on antipsychotic medication. Method: A descriptive cross-sectional study was conducted in which a group of 220 patients aged 8-17 years, diagnosed with a mental disorder and on antipsychotic treatment. They were compared to a control group of 199 asthmatic patients not exposed to antipsychotic drugs. Data was extracted from the computerised clinical history ECAP in 2013. Results: The mean age of the children was 12 years (8-17). Risperidone (67%) was the most frequent treatment. The recording of Body Mass Index (BMI) and blood pressure (AP) was 50% in Mental Disorder (MD) patients. A higher number of cardiovascular monitoring physical parameters (weight, height, BMI and BP) were observed in the MD group compared to the control Asthma control group. Altogether, more physical parameters than biochemistry parameters were recorded. Conclusions: This study shows that the recording of cardiovascular parameters and metabolic studies needs to be improved in children and adolescents on treatment with antipsychotics.
KW - Antipsychotic
KW - Mental disorder
KW - Metabolic syndrome
KW - Paediatric age
KW - cardiovascular risk
U2 - 10.1016/j.rpsm.2016.05.001
DO - 10.1016/j.rpsm.2016.05.001
M3 - Article
C2 - 27291832
SN - 1888-9891
VL - 11
SP - 19
EP - 26
JO - Revista de Psiquiatria y Salud Mental
JF - Revista de Psiquiatria y Salud Mental
IS - 1
ER -